GlucosamineNCT07843342
Human Absorption Study of Liposomal Glucosamine Supplements
A study testing High-Emulsified Liposomal Glucosamine Liquid, Low-Emulsified Liposomal Glucosamine Liquid and Glucosamine Liquid without Liposomal in people with Glucosamine and Liposomal Encapsulation, run by TCI Co., Ltd. at 1 site in Taiwan.
Trial summary
The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Glucosamine, Liposomal Encapsulation
- What is being tested?
- High-Emulsified Liposomal Glucosamine Liquid, Low-Emulsified Liposomal Glucosamine Liquid and Glucosamine Liquid without Liposomal
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteTaiwan
- Study dates
- 21 Oct 2026to 29 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged ≥18 years, regardless of sex, who are willing to sign the informed consent form and are able to fully comply with all study procedures.
Who cannot join
- Pregnant or breastfeeding women, or individuals who are unwilling to use a physical method of contraception during the study period, such as condoms or an intrauterine device.
- Employees of TCI Co., Ltd. and their family members.
- Individuals who have regularly taken any supplements or medications containing glucosamine or N-acetylglucosamine (N-acetyl-glucosamine) within 14 days prior to study initiation, defined as use for ≥7 consecutive days.
- Individuals with a history of chronic gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), chronic diarrhea, Crohn's disease, celiac disease, bowel control problems/fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, or ulcerative colitis; a history of epilepsy or seizures; liver or kidney disease; malignancy; endocrine disorders; psychiatric disorders; alcohol or substance abuse; or other significant organic diseases, as determined based on medical history.
- Individuals with a history of gastrointestinal surgery, organ transplantation, or other major surgery.
- Individuals who have experienced acute gastroenteritis within 2 weeks prior to study initiation.
- Individuals with a history of allergy to any ingredient in the investigational products. The investigational products contain shrimp- and soy-derived ingredients.
- Vegetarians, as the glucosamine used in this study is derived from shrimp.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
TCI Co., Ltd
Taipei, 114
Ping Lin, +886 02-8797-7811, candice.lin@tci-bio.com
About this study
Official title: Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans.
Read the detailed description
This study is a single-center, self-controlled crossover human trial designed to evaluate the differences in blood concentration changes and bioavailability following a single oral dose of glucosamine supplements.
Healthy adult participants aged 18 years and older will be enrolled. Each participant will complete four study sessions, with a minimum washout period of 7 days between sessions. On each study day, venous blood samples will be collected prior to test product administration (0 minutes) to assess glucosamine levels, complete blood count, blood lipids, blood glucose, and liver and kidney function indicators.
After baseline blood collection, a standardized breakfast will be provided and consumed within 10 minutes, followed by administration of the test product. Venous blood samples will then be collected at 0.5, 1, 2, 4, 8, and 24 hours post-intake to measure glucosamine concentrations. Lunch will be provided after the 4-hour blood draw, and dinner will be provided after the 8-hour blood draw. Identical meals will be provided on four study sessions.
- Conditions
- Glucosamine, Liposomal Encapsulation
- Being tested
- High-Emulsified Liposomal Glucosamine Liquid, Low-Emulsified Liposomal Glucosamine Liquid, Glucosamine Liquid without Liposomal, Glucosamine Tablet without Liposomal
- Keywords
- glucosamine, liposomal, human bioavailability, Double Nutri
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-Emulsified Liposomal Glucosamine LiquidDietary supplement
Also called High-Emulsified Double Nutri Glucosamine Liquid
The formulation primarily consists of glucosamine HCl, a high proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology.
Low-Emulsified Liposomal Glucosamine LiquidDietary supplement
Also called Low-Emulsified Double Nutri Glucosamine Liquid
The formulation primarily consists of glucosamine HCl, a low proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology.
Glucosamine Liquid without LiposomalDietary supplement
The formulation primarily consists of glucosamine HCl and is not processed using the patented Double Nutri Liposomal technology.
Glucosamine Tablet without LiposomalDietary supplement
The tablet formulation primarily consists of glucosamine HCl and is not processed using liposomal technology.
| Study group | Role | What they receive |
|---|---|---|
| High-Emulsified Liposomal Glucosamine Liquid | Experimental | One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. Receives: Dietary Supplement: High-Emulsified Liposomal Glucosamine Liquid |
| Low-Emulsified Liposomal Glucosamine Liquid | Experimental | One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. Receives: Dietary Supplement: Low-Emulsified Liposomal Glucosamine Liquid |
| Glucosamine Liquid without Liposomal | Active comparator | One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. Receives: Dietary Supplement: Glucosamine Liquid without Liposomal |
| Glucosamine tablet without Liposomal | Active comparator | Three tablets will be administered per dose, with each tablet containing 500 mg of glucosamine. Receives: Dietary Supplement: Glucosamine Tablet without Liposomal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma glucosamine level (ng/mL)
Plasma glucosamine levels will be measured at fasting and at 0.5, 1, 2, 4, 8, and 24 hours post-intake.
Measured: at 24 hours after taking test sample
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2026
- Study start21 Oct 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion29 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlucosamineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- TCI Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Tong-Lin Wu, Principal investigator, TCI Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07843342
- Sponsor's protocol ID
- 26-088-A
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
- ClinicalTrials.gov ID
- NCT07843342
- Acronym / sponsor ID
- 26-088-A
- Conditions
- Glucosamine, Liposomal Encapsulation
- Keywords
- glucosamine, liposomal, human bioavailability, Double Nutri
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- TCI Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 21 Oct 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 29 Jan 2027 (estimated)
- First posted
- 28 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans.
Detailed description
This study is a single-center, self-controlled crossover human trial designed to evaluate the differences in blood concentration changes and bioavailability following a single oral dose of glucosamine supplements.
Healthy adult participants aged 18 years and older will be enrolled. Each participant will complete four study sessions, with a minimum washout period of 7 days between sessions. On each study day, venous blood samples will be collected prior to test product administration (0 minutes) to assess glucosamine levels, complete blood count, blood lipids, blood glucose, and liver and kidney function indicators.
After baseline blood collection, a standardized breakfast will be provided and consumed within 10 minutes, followed by administration of the test product. Venous blood samples will then be collected at 0.5, 1, 2, 4, 8, and 24 hours post-intake to measure glucosamine concentrations. Lunch will be provided after the 4-hour blood draw, and dinner will be provided after the 8-hour blood draw. Identical meals will be provided on four study sessions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| High-Emulsified Liposomal Glucosamine Liquid | Experimental | Dietary Supplement: High-Emulsified Liposomal Glucosamine LiquidOne sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. |
| Low-Emulsified Liposomal Glucosamine Liquid | Experimental | Dietary Supplement: Low-Emulsified Liposomal Glucosamine LiquidOne sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. |
| Glucosamine Liquid without Liposomal | Active comparator | Dietary Supplement: Glucosamine Liquid without LiposomalOne sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. |
| Glucosamine tablet without Liposomal | Active comparator | Dietary Supplement: Glucosamine Tablet without LiposomalThree tablets will be administered per dose, with each tablet containing 500 mg of glucosamine. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adults aged ≥18 years, regardless of sex, who are willing to sign the informed consent form and are able to fully comply with all study procedures.
Key exclusion criteria (8 listed)
- Pregnant or breastfeeding women, or individuals who are unwilling to use a physical method of contraception during the study period, such as condoms or an intrauterine device.
- Employees of TCI Co., Ltd. and their family members.
- Individuals who have regularly taken any supplements or medications containing glucosamine or N-acetylglucosamine (N-acetyl-glucosamine) within 14 days prior to study initiation, defined as use for ≥7 consecutive days.
- Individuals with a history of chronic gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), chronic diarrhea, Crohn's disease, celiac disease, bowel control problems/fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, or ulcerative colitis; a history of epilepsy or seizures; liver or kidney disease; malignancy; endocrine disorders; psychiatric disorders; alcohol or substance abuse; or other significant organic diseases, as determined based on medical history.
- Individuals with a history of gastrointestinal surgery, organ transplantation, or other major surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-Emulsified Liposomal Glucosamine LiquidAlso: High-Emulsified Double Nutri Glucosamine LiquidThe formulation primarily consists of glucosamine HCl, a high proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology. | Dietary supplement | High-Emulsified Liposomal Glucosamine Liquid |
| Low-Emulsified Liposomal Glucosamine LiquidAlso: Low-Emulsified Double Nutri Glucosamine LiquidThe formulation primarily consists of glucosamine HCl, a low proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology. | Dietary supplement | Low-Emulsified Liposomal Glucosamine Liquid |
| Glucosamine Liquid without LiposomalThe formulation primarily consists of glucosamine HCl and is not processed using the patented Double Nutri Liposomal technology. | Dietary supplement | Glucosamine Liquid without Liposomal |
| Glucosamine Tablet without LiposomalThe tablet formulation primarily consists of glucosamine HCl and is not processed using liposomal technology. | Dietary supplement | Glucosamine tablet without Liposomal |
Primary outcome
Plasma glucosamine level (ng/mL)
Time frame: at 24 hours after taking test sample
Plasma glucosamine levels will be measured at fasting and at 0.5, 1, 2, 4, 8, and 24 hours post-intake.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
Related trials for Glucosamine
Not yet recruiting
A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
Knee Pain Chronic
Recruiting
NT-II™ Collagen for Joint Discomfort and Function
Activity-Related Knee Discomfort, Joint Discomfort
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tong-Lin Wu principal investigator
TCI Co., Ltd.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High-Emulsified Liposomal Glucosamine Liquid, Low-Emulsified Liposomal Glucosamine Liquid and Glucosamine Liquid without Liposomal in people with Glucosamine and Liposomal Encapsulation, run by TCI Co., Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tong-Lin Wu (+886 02-87977811, Tony.Wu@tci-bio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma glucosamine level (ng/mL) (time frame: at 24 hours after taking test sample). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.